CSF3 and Miyoshi myopathy: Considering the results of the current study, it is suggested that both single-dose etoposide plus G-CSF and G-CSF alone, followed by risk-adapted plerixafor are acceptable mobilizations in patients with MM who are expected to receive at least one course of ASCT.